| 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 临床试验(元) | 168,155,131.19 | 99,817,331.20 | 148,950,077.32 | 82,612,394.23 |
| 医药研发(元) | 187,747,174.95 | 86,230,674.39 | 203,577,353.93 | 94,418,918.40 |
| 租赁及物业服务(元) | 26,711,590.67 | 13,520,197.68 | 28,403,266.48 | 14,254,693.05 |
| 其他收入(元) | 4,819,358.43 | 1,893,728.53 | 2,544,294.25 | 3,128,150.60 |
| 营业成本(元) | ||||
| 临床试验(元) | 107,502,105.18 | 64,589,295.90 | 98,610,293.18 | 60,562,859.95 |
| 医药研发(元) | 99,319,574.16 | 35,701,269.61 | 86,392,706.37 | 39,130,458.63 |
| 租赁及物业服务(元) | - | - | - | - |
| 其他收入(元) | 4,689,332.81 | 1,956,578.74 | 3,292,698.64 | 2,871,605.41 |
| 毛利(元) | ||||
| 临床试验(元) | 60,653,026.01 | 35,228,035.30 | 50,339,784.14 | 22,049,534.28 |
| 医药研发(元) | 88,427,600.79 | 50,529,404.78 | 117,184,647.56 | 55,288,459.77 |
| 租赁及物业服务(元) | 26,711,590.67 | - | - | - |
| 其他收入(元) | 130,025.62 | -62,850.21 | -748,404.39 | 256,545.19 |
| 毛利率(%) | ||||
| 临床试验(%) | 36.07 | 35.29 | 33.80 | 26.69 |
| 医药研发(%) | 47.10 | 58.60 | 57.56 | 58.56 |
| 租赁及物业服务(%) | - | - | - | - |
| 其他收入(%) | 2.70 | -3.32 | -29.42 | 8.20 |
| 收入构成(%) | ||||
| 临床试验(%) | 43.40 | 49.55 | 38.84 | 42.49 |
| 医药研发(%) | 48.46 | 42.80 | 53.09 | 48.57 |
| 租赁及物业服务(%) | 6.89 | 6.71 | 7.41 | 7.33 |
| 其他收入(%) | 1.24 | 0.94 | 0.66 | 1.61 |
| 毛利构成(%) | ||||
| 临床试验(%) | 34.48 | 41.11 | 30.18 | 28.42 |
| 医药研发(%) | 50.27 | 58.96 | 70.26 | 71.25 |
| 租赁及物业服务(%) | 15.18 | 0.00 | 0.00 | 0.00 |
| 其他收入(%) | 0.07 | -0.07 | -0.45 | 0.33 |